Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT07690579

Conditions

Prostate Cancer

Prostate Cancer Recurrent

Prostate Metastases

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Questionnaires

Medical Record Review

Study Details

Brief summary:

Prostate Cancer (PC) is the most common non-cutaneous malignancy diagnosed and second leading cause of cancer death among men across the United States. PC among Black men accounts for a higher proportion alike of cancer diagnoses and deaths. In the prostate specific antigen (PSA)-based screening era, mortality rates improved at a similar velocity among Black and White men, but the 2- to 3-fold excess mortality burden borne by Black men has persisted over the past 40 years, the second highest among all major cancers. In recent years mortality is rising among Black men, and at a rapid velocity.

The explanations for this disparity-the extent to which it is attributable to genetics, environmental factors including Structural and Social Determinants of Health (SSDH), or access to care-are multifactorial and have been elucidated to a limited extent. A large meta-analysis recently found that across dozens of studies and cohorts, greater adjustment for clinical and SSDH factors generally resulted in race itself dropping as a significant predictor.

These and other findings suggest that the determinants of disparity be identified at time of, and prior to, cancer diagnosis, and that both genetic and environmental factors contribute to earlier development and progression.

Conditions

Prostate Cancer

Prostate Cancer Recurrent

Prostate Metastases

Study ID

NCT07690579

Start date

Mar 31, 2026

Status verified date

Jun, 2026

Completion date

Mar 31, 2028

Anticipated

Primary completion date

Mar 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants who have elected radical prostatectomy as prostate cancer treatment.
  • Participants who have agreed to participate in the Urology Biobank.

Exclusion Criteria:

  • Participant does not plan nor schedule a radical prostatectomy (RP) procedure.

Study Design

Enrollment

350 participants

Anticipated

Interventions and Outcome Measures

Arms

Men with prostate cancer

Participants who have planned or completed a non-investigational radical prostatectomy will be asked to complete a series of questionnaires online covering a subset of community-informed SSDH measures and individual exposures. Responses will be recorded in a secured database. . It will take about up to 2 hours to complete the surveys. There will be questions about your demographics (education level, income, employment, etc.); health care access and quality; lifestyle and behaviors. Data from your medical record about your prostate cancer and treatment will also be collected.

Interventions

Questionnaires

Participants will receive surveys to complete online via a secure system.

Medical Record Review

Data will be collected from participants medical charts which includes disease history, pathological findings, and other disease characteristics.

Primary outcome measure

  • Identification of not yet identified factors contributing to prostate cancer [ Time Frame: Up to 2 years ]

Central Contacts and Locations

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Principal Investigator:

Mathew Cooperberg, MD, MPH

More Information

Sponsor

University of California, San Francisco

Last update posted

Jul 8, 2026

Last verified

Jun, 2026

Keywords

  • Radical Prostatectomy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-07-08.